期刊文献+

西尼地平大鼠在体肠吸收药物动力学研究

Intestinal absorption pharmacokinetics of cilnidipine in rats
下载PDF
导出
摘要 目的研究西尼地平在大鼠各肠段的药物动力学吸收特点。方法采用大鼠在体肠灌流实验装置,利用紫外-可见分光光度法和HPLC法分别测定酚红和西尼地平的含量。结果西尼地平在十二指肠、空肠、回肠、结肠的吸收速率分别为(2.05±0.013)、(1.95±0.010)、(1.96±0.005)、(1.82±0.005)h-1;药物质量浓度为5、10、15 mg·L-1时,在肠的吸收速率常数分别为(2.25±0.006 9)、(2.24±0.005 3)、(2.24±0.005 7)h-1;当pH值为6.4、7.2、7.9时,肠的吸收速率常数分别为(2.23±0.012 3)、(2.24±0.005 3)、(2.21±0.213 1)h-1。结论不同质量浓度的西尼地平在大鼠全肠道的吸收无显著差异,吸收机制为被动扩散;西尼地平在各肠段吸收较好。 Objective To investigate the absorption pharmacokinetics of cilnidipine at different intestine segments in rats.Methods The intestine in rats was cannulated for in situ perfusation.UV and HPLC were used to determine the concentrations of phenol red and cilnidipine,respectively.Results The absorption rate constants(ka) at duodenum,jejunum,ileum,and colon were(2.05±0.013)h-1,(1.95±0.010) h-1,(1.96±0.005) h-1,(1.82±0.005) h-1respectively.The ka from intestine at cilnidipine concentration of 5 mg·L-1,10 mg·L-1,15mg·L-1were(2.25±0.006 9) h-1,(2.24±0.005 3) h-1,(2.24±0.005 7) h-1; ka at pH of 6.4,7.2,7.9 were(2.23±0.0123) h-1,(2.24±0.0053) h-1,(2.21±0.2131) h-1.Conclusion The effects of the different concentrations on the cilnidipine absorption kinetics were not significant.The absorption of cilnidipine from intestine was a process with passive diffusion michanism.Cilnidipine was well absorbed at all segments of intestine in rats.
出处 《中国药剂学杂志(网络版)》 2006年第6期284-289,共6页 Chinese Journal of Pharmaceutics:Online Edition
关键词 药剂学 药物动力学 高效液相色谱法 西尼地平 吸收速率常数 小肠 pharmaceutics pharmacokinetics HPLC cilnidipine absorption rate constant intestine
  • 相关文献

参考文献6

二级参考文献16

  • 1施毅,康晓明,储小曼,夏锡荣,卓海通,刘堃.环丙沙星和氧氟沙星对氨茶碱药代动力学的影响[J].中国临床药理学杂志,1994,10(4):206-210. 被引量:13
  • 2钟淑卿 莫红樱 张永昶 等.氟喹诺酮类对缓释茶碱茶喘平药动学的影响[J].中华结核和呼吸杂志,1995,18(4):240-240.
  • 3[1]F Capsoni,F Minonzio,A Mongari, et al. Evaulation of the kinetics of the imunomodulation activity of pidotimod on human[J].Neutrophils pharmacol,Res,1992,26(Suppl 2):172.
  • 4[2]Barchielli,M,Coppi G.et al.Experimental studies on PGT/1A,a new immunostimulating drug[J].Eur J Pharmacol, 1990,183:909.
  • 5[3]P Careddu,V Mei,Venturoli,et al. Pidotimod in the treatment of recurrent respiratory infections in the paediatric patients[J].ArzneimforForsch/Drug Res, 1994,44:1 485.
  • 6[4]G Motta, E De Campora C,De Vita,et al. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood[J].Arzneim-Forsch/Drug Res,1994,44:1 521.
  • 7[5]E Clemente,R Solli,V Mei, et al. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infections in children[J].Arzneim-Forsch/Drug Res, 1994,44:1 490.
  • 8[6]E Pozzi, A Dolcetti, O Orlandi, et al. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchiyis[J].Arzneim-Forsch/Drug Res, 1994,44:1 495.
  • 9[7]G P benetti,M IIIeni,A Passera,et al. Exvivo evaluation of pidotimod activity in patient with chronic obstructive pulmonary disease[J].Arzneim-Forsch/Drug Res, 1994,44:1 503.
  • 10Stab H. Moxifloxacin-review of clinical pharrnacokinetics metabolism and excretion,Poster at First International Moxiflixacia Symposium[ C ]. Berlin: Bayer, 1993,3 : 1986.

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部